CD274 and sarcoma: The presence of TLSs in a variety of tumors, including sarcomas, can predict the prognosis of patients and the efficacy of immunotherapy [4, 5] and is expected to supplement the immunohistochemical evaluation of programmed cell death-ligand 1 (PD-L1), which together guide immunotherapy.